FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive Patients Noninferior to Continued DTG/ABC/3TC at Week 48

March 4-7, 2019; Seattle, Washington
Higher patient-reported satisfaction with monthly injectable dual regimen compared with daily oral tablets.
Format: Microsoft PowerPoint (.ppt)
File Size: 210 KB
Released: March 11, 2019

Acknowledgements

Directly provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This program is supported by independent educational grants from
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Related Content

Dr Sylvia Ojoo discusses data on cryptococcal meningitis in people with HIV from the fall 2022 HIV conferences, from Clinical Care Options (CCO)

person default Sylvia Ojoo, CCST (UK), MRCP (UK), DTM&H (UK), DFFP (UK), MBChB Released: December 6, 2022

Dr Monica Gandhi discusses key advances in HIV treatment over the past year, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 2, 2022

A patient advocate discusses the importance of community-led HIV treatment and prevention, from Clinical Care Options (CCO)

person default Rena Janamnuaysook, MBA Released: December 2, 2022

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Released: November 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings